Tuberculosis tests market to reach $442 million by 2030, says GlobalData

World Tuberculosis (TB) Day, observed annually on 24 March, highlights the devastating lives lost due to TB. Despite the fact that 74 million lives have been saved since 2000 due to increased global efforts, there were still 10.6 million TB cases and 1.6 million TB-associated deaths in 2021, according to the World Health Organization (WHO). The WHO’s TB strategy created in 2014 highlights the targets for 2035. Globally, the number of TB deaths needs to reduce by 95% and the incidence of TB infection by 90%, compared to 2015. To reach these targets, there needs to be a global effort to increase surveillance via testing and vaccinations, especially in low- and middle-income countries. As a result, the global TB test market is forecast to reach $441.8 million by 2030, according to GlobalData’s Mycobacterium Tuberculosis Tests market model.

Selena Yu, Medical Analyst, at GlobalData, comments: “World TB Day emphasizes not only the need for global support in countries with endemic TB but also to keep non-endemic countries TB cases low. We are seeing people living in non-endemic TB countries vaccinate less due to a lack of worries about the deadly disease. Therefore, non-endemic countries need more screening to combat the rise in anti-vaxxers. Additionally, there is a lack of medical screening for tourists and other visitors to non-endemic countries who may be carrying TB. In endemic regions, there is a need for rapid tests that rely on little equipment to allow for remote testing. Additionally, increased vaccination in endemic regions is also needed to combat TB.”

According to GlobalData’s Mycobacterium Tuberculosis Tests market model, Qiagen held 33.8% of the global TB tests market in 2022, with Oxford Immunotec as second with 14.3%. GlobalData covers interferon-gamma release assays (IGRA) and singleplex nucleic acid amplification tests (NAATs) in the model. However, with more multiplex tests for respiratory diseases being released, there may be an increase in the market share held by multiplex tests in the near future.

Yu concludes: “Multiplex tests such as the CRISPR-Based COVID-19 Diagnostic Device by Ford Motor Co., which tests for COVID-19, TB, and Escherichia coli (E.coli), may gain market share in the next decade as many respiratory diseases have similar symptoms and the multiplex technology limits the time needed to diagnose and treat a patient.”

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we're very happy to help.



DECODED Your daily industry news round-up

This site is registered on wpml.org as a development site.